A brief discussion on the safety factors in managing infectious biospecimen conservation-take the monkeypox as an example

doi:10.19871/j.cnki.xfcrbzz.2023.04.003

Abstract

Abstract: Mpox is a zoonotic infectious disease caused by mpox virus (MPXV). Mpox virus is a double-stranded DNA virus of the genus orthopoxvirus that can be spread by infectious people, infected animals, and contaminated objects. For the first time since May 2022, mpox virus has spread widely in multiple regions outside of Central and West Africa. The World Health Organization declared mpox as an "internationally concerning public health emergency" in July 2022. However, on May 11, 2023, they announced that the mpox outbreak no longer constitutes an "internationally concerning ongoing public health emergency." This indicates that there has been great progress globally in controlling the mpox outbreak. As of June 12, 2023, a total of 87 979 cases have been reported worldwide. The first imported mpox case in mainland China was admitted to the Chongqing Public Health Medical Center in September, 2022, and the remaining samples from the clinical diagnosis and treatment were preserved in the biobank of the center. Four cases of the mpox virus infection have been reported from Beijing and Guangzhou in June 2023, respectively. Currently, the mpox outbreak in our country is in the sporadic transmission phase. Based on the main characteristics of mpox virus, this paper takes the whole-process management of mpox samples stored in biobank as an example, briefly analyzes the safety factors for managing infectious biospecimen from the aspects of the protection of operators, the protection of the surrounding environment and the guarantee of the quality of stored samples, so as to provide reference for future preservation of mpox and related infectious samples.

Key words: Monkeypox virus, Infectious bio-specimen, Conservation, Biosafety

CLC Number:

R511
R197.38

Yang Sen, Shen Yan, Xia Chengshuang, Chen Yaokai, Chen Yemiao. A brief discussion on the safety factors in managing infectious biospecimen conservation-take the monkeypox as an example[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(4): 10-14.

References

[1] KOZLOV M.Monkeypox outbreaks: 4 key questions researchers have[J]. Nature, 2022, 606(7913): 238-239.
[2] KUMAR N, ACHARYA A, GENDELMAN HE, et al.The 2022 outbreak and the pathobiology of the monkeypox virus[J]. J Autoimmun, 2022, 131:102855.
[3] WORLD HEALTH ORGANIZATION.2022-23 Mpox (Monkeypox) Outbreak: Global Trends Geneva: World Health Organization, 2023[EB/OL].[2023-06-13].https://worldhealthorg.shinyapps.io/mpx_global/.
[4] 王长泰,刘林娜,赵令斋,等.《猴痘诊疗指南(2022年版)》解读[J/CD].新发传染病电子杂志,2022, 7(3):12-17.
[5] KABUGA AI, EI ZOWALATY ME.A review of the monkeypox virus and a recent outbreak of skin rash disease in Nigeria[J]. J Med Virol, 2019, 91(4): 533-540.
[6] BUNGE EM, HOET B, CHEN L, et al.The changing epidemiology of human monkeypox-A potential threat? A systematic review[J]. PLoS Negl Trop Dis, 2022, 16(2): e0010141.
[7] LI H, ZHANG H, DING K, et al.The evolving epidemiology of monkeypox virus[J]. Cytokine Growth Factor Rev, 2022, 68: 1-12.
[8] ADALJA A, INGLESBY T.A Novel International Monkeypox Outbreak[J]. Ann Intern Med, 2022, 175(8): 1175-1176.
[9] ALAKUNLE E, MOENS U, NCHINDA G, et al.Monkeypox Virus in Nigeria: Infection Biology, Epidemiology, and Evolution[J]. Viruses, 2020, 12(11): 1257.
[10] PETERSEN E, KANTELE A, KOOPMANS M, et al.Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention[J]. Infect Dis Clin North Am, 2019, 33(4): 1027-1043.
[11] SIEGRIST EA, SASSINE J.Antivirals With Activity Against Mpox: A Clinically Oriented Review[J]. Clin Infect Dis, 2023, 76(1):155-164.
[12] YANG Z.Monkeypox: A potential global threat?[J]. J Med Virol, 2022, 94(9):4034-4036.
[13] REYNOLDS MG, DAMON IK.Outbreaks of human monkeypox after cessation of smallpox vaccination[J]. Trends Microbiol, 2012, 20(2):80-87.
[14] 国家卫生健康委员会. 猴痘防控技术指南(2022年版)[EB/OL].[2022-07-01].https://www.gov.cn/fuwu/2022-07/01/content_5698882.htm.
[15] 陈叶苗,景一娴,杨森,等. 人类遗传资源保藏审批行政许可现状与申报要点分析[J]. 中国医药生物技术,2022,17(6): 551-555.
[16] 郑君,杨志云,张伟,等. 医院实验室样本的生物安全管理问题及对策[J]. 标记免疫分析与临床,2021,28(8):1426-1429.
[17] 国国家卫生健康委员会. 高致病性病原微生物运输[EB/OL].[2022-11-08]. https://zwfw.nhc.gov.cn/bsp/gzbxby wswys/202011/t20201124_1521.html.
[18] 李万莎,邵坤宁,刘晶哲. 构建核酸实验室生物安全智能管理系统的设计和研究[J/CD]. 新发传染病电子杂志,2021, 6(4):352-355.
[19] 余永国,周学迅,郭爱华,等. 生物样本库的安全管理措施[J].转化医学杂志,2013,2(2):103-105.
[20] 刘妍,张小燕,林爱芬,等. 生物样本库建设过程中生物安全和生物危害指导文件——了解生物安全等级,满足生物样本库安全要求[J]. 中国医药生物技术,2020,15(2): 139-143.
[21] 郑君,杨志云,王雅杰,等. 医院实验室生物安全管理策略[J].标记免疫分析与临床,2021,28(1):144-146.